Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

COPENHAGEN, Denmark I March 10, 2025 I Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise ...

TSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

The purpose of Phase 2 Expansion Part B is to assess the objective response rate of HexaBody-CD38 versus subcutaneous ... pipeline including bispecific T-cell engagers, antibody-drug conjugates ...

CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

Inc. , today announced a definitive merger agreement under which Bristol Myers Squibb ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.